News

Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate
Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...
Biogen rises as Alzheimer’s therapy drives Q2 beat
Biogen (NASDAQ:BIIB) traded ~8% higher in the premarket on Thursday after the company posted better-than-expected financials ...
Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio
Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...
StockStory.org on MSN4d
Biogen Earnings: What To Look For From BIIB
Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Thursday morning. Here’s what you need to know. Biogen ...
Biogen lifts full-year outlook amid Alzheimer’s drug strength, sending shares up
Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...
Biogen signals Leqembi sales gaining momentum, lifts profit forecast
Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...
2BIIB : Beyond The Numbers: 8 Analysts Discuss Biogen Stock
In the preceding three months, 8 analysts have released ratings for Biogen BIIB -0.98% Get Free Report , presenting a wide ...
Nasdaq2mon
September 2026 Options Now Available For Biogen (BIIB)
Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the September 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay ...